Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
Michigan Institute of Urology is a clinical trial site for LEGION-100
Detroit, Mich. (March 31, 2025)—Michigan Institute of Urology (MIU), the largest and most well-established urology practice in Southeast Michigan, has been designated as a clinical trial site to assess the safety and effectiveness of an investigational combination immunotherapy designed to activate the immune system and eliminate prostate cancer cells throughout the body.
The investigational therapy, SYNC-T® Therapy SV-102, is intended for patients with metastatic castration-resistant prostate cancer. This condition involves prostate cancer that has spread to other parts of the body and continues to progress despite low testosterone levels. Patients whose prostate cancer has spread elsewhere in their body and who are already taking daily prostate cancer medications for their condition may be eligible for this investigational study.
The LEGION-100 trial aims to evaluate the safety and efficacy of SYNC-T® Therapy SV-102. This therapy freezes a portion of the target tumor to release its cell contents. A multi-target immunotherapy drug is then infused directly into the tumor. This minimally invasive procedure is intended to stimulate the immune system to fight cancer throughout the body.
“MIU is dedicated to providing our patients with the latest technology and being at the forefront of prostate cancer treatment. LEGION-100 is an investigational Phase 2a trial that uses a novel mechanism of action, which has already shown strong clinical responses in early clinical data,” said MIU Chief Medical Officer and Principal Investigator Jason Hafron, M.D
MIU is the only site in Michigan chosen to participate in this clinical trial. To find out more about the participation criteria and study plan, patients and/or physicians should visit ClinicalTrials.gov to review the study record NCT06533644 or contact the research Team at (248) 786-0467 or by email research@michiganurology.com.
About Michigan Institute of Urology (MIU)
Michigan Institute of Urology, the largest urology practice in Southeast Michigan, is a well-established leader in urological care. MIU operates 19 locations. In addition to its 42 general and fellowship-trained urologists, MIU has a full complement of compassionate and caring nurse practitioners, registered nurses, medical assistants, and ancillary personnel. It is one of the leading urology practices in the United States, utilizing the latest clinically proven techniques to diagnose and treat many urologic disorders in men, women, and children. Learn more at michiganurology.com.
